Regeneron (REGN) PRALUEN Panel Commentary Could Result in Narrower-Than-Expected Labeling, BMO Capital Says

BMO Capital analyst Jim Birchenough reiterated a Market Perform rating and $381 price target on Regeneron Pharma (NASDAQ: REGN) following yesterday's FDA panel review of PRALUEN.

Birchenough commented, "While the ultimate vote was positive and should support approval, we believe that panel member commentary could result in narrower-than-expected labeling. In particular, we see a reasonable likelihood of initial labeling restricted to 900,000 patients with HeFH. We continue to expect a slow launch and would take a wait-and-see approach to labeling."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $526.09 yesterday.

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $1,030 at TD Cowen
• Equity Residential (EQR) PT Raised to $70 at Evercore ISI
• Boeing (BA) PT Lowered to $240 at Stifel